Axsome Therapeutics Inc(AXSM)stock report

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

AXSM pipelines

Finance:
Market Cap:3300M; Shares Outstanding:37.0M; Short Interest: 17.61%; Q3 2019(9/30/19): Cash 43.64M. Loss 19.14M

EPS and Sales:
https://finance.yahoo.com/quote/AXSM/financials?p=AXSM

Date EPS % last year % last quarter
2018.12.31 -1.15 9.45% 38.55%
2019.3.31 -0.32 -68.42% 72.17%
2019.6.30 -0.73 -43.14% -9.00%
2019.9.30 -1.29 -55.42% -76.71%

 

Sale:0

Insider Transactions:
http://insidercow.com/history/company.jsp?company=AXSM&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/AXSM/institutional-ownership/

2019.12.09:
Total institutions: 127,no change
Shares hold: 18829.3k shares. no change
shares% hold: 54.56%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/AXSM/price-targe

NEWS:

2020.01.18:Axsome Had A Monumental Run, But Its Long-Term Potential Has Only Begun

2020.01.15: 2 Top Growth Stocks to Buy in January

2020.01.13: Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

2020.01.07: Axsome Therapeutics: Buy at the High?

Leave a Reply